4-(2-Methylpropyl)-2-phenyl-1,3-thiazole | 1218937-20-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(2-Methylpropyl)-2-phenyl-1,3-thiazole
• CAS: 1218937-20-2
• 化学式: C₁₃H₁₅NS
• 分子量: 217.335
• InChiKey: SJMJKWVPQYUNEV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  在 manganese(IV) oxide 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 12.0h， 以90%的产率得到4-(2-Methylpropyl)-2-phenyl-1,3-thiazole
  参考文献：
  名称：

  使用 MnO2 轻松合成 2,4-二取代噻唑

  摘要：

  通过二氧化锰 (MnO2) 氧化相应的噻唑啉，可以方便地合成具有给电子和吸电子基团的结构多样的噻唑。研究了 2 位和 4 位取代的影响。在2-或4-位具有芳基或乙烯基取代基的所需噻唑可以良好到极好的产率获得。

  DOI：

  10.3390/molecules14124858

文献信息

• Inhibitors of ADAMTS4 or ADAMTS5 for use in preventing or treating cardiac remodeling and chronic heart failure
  申请人：Universitetet i Oslo

  公开号：US10322143B2

  公开（公告）日：2019-06-18

  The present invention provides an inhibitor of an ADAMTS proteoglycanase for use in treating or preventing cardiac remodeling or for use in treating or preventing heart failure in a subject. In particular, the present invention provides an inhibitor of ADAMTS4 or ADAMTS5 for use in treating or preventing cardiac remodeling or chronic heart failure in a subject with cardiac remodeling or with chronic heart failure, or with a condition that may lead to cardiac remodeling and/or chronic heart failure. Also provided is a method of treating or preventing cardiac remodeling or treating or preventing heart failure which method comprises administering to a subject in need thereof a therapeutically effective amount of an inhibitor of an ADAMTS proteoglycanase. Also provided is the use of an inhibitor of an ADAMTS proteoglycanase in the manufacture of a medicament for treating or preventing cardiac remodeling or treating or preventing heart failure.

  本发明提供了一种ADAMTS蛋白聚糖酶抑制剂，用于治疗或预防心脏重塑或用于治疗或预防受试者的心力衰竭。特别是，本发明提供了一种ADAMTS4或ADAMTS5的抑制剂，用于治疗或预防患有心脏重塑或慢性心力衰竭或可能导致心脏重塑和/或慢性心力衰竭的病症的受试者的心脏重塑或慢性心力衰竭。还提供了一种治疗或预防心脏重塑或治疗或预防心衰的方法，该方法包括向有需要的受试者施用治疗有效量的 ADAMTS 蛋白聚糖酶抑制剂。还提供了一种ADAMTS蛋白聚糖酶抑制剂在制造治疗或预防心脏重塑或治疗或预防心衰的药物中的用途。
• COMT inhibiting methods and compositions
  申请人：LIEBER INSTITUTE FOR BRAIN DEVELOPMENT

  公开号：US10934283B2

  公开（公告）日：2021-03-02

  Compounds that inhibit COMT enzyme and pharmaceutical compositions comprising the same are provided herein. Methods of treating various psychiatric and neurological disorders with the compounds and pharmaceutical compositions described herein are also provided.

  本文提供了抑制 COMT 酶的化合物和包含这些化合物的药物组合物。本文还提供了使用本文所述化合物和药物组合物治疗各种精神和神经疾病的方法。
• SPIROINDALONES
  申请人：Fletcher Joan M.

  公开号：US20100137297A1

  公开（公告）日：2010-06-03

  The present invention relates to spiroindalone compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
• INHIBITORS OF ADAMTS4 OR ADAMTS5 FOR USE IN PREVENTING OR TREATING CARDIAC REMODELING AND CHRONIC HEART FAILURE
  申请人：UNIVERSITETET I OSLO

  公开号：US20160158271A1

  公开（公告）日：2016-06-09

  The present invention provides an inhibitor of an ADAMTS proteoglycanase for use in treating or preventing cardiac remodeling or for use in treating or preventing heart failure in a subject. In particular, the present invention provides an inhibitor of ADAMTS4 or ADAMTS5 for use in treating or preventing cardiac remodeling or chronic heart failure in a subject with cardiac remodeling or with chronic heart failure, or with a condition that may lead to cardiac remodeling and/or chronic heart failure. Also provided is a method of treating or preventing cardiac remodeling or treating or preventing heart failure which method comprises administering to a subject in need thereof a therapeutically effective amount of an inhibitor of an ADAMTS proteoglycanase. Also provided is the use of an inhibitor of an ADAMTS proteoglycanase in the manufacture of a medicament for treating or preventing cardiac remodeling or treating or preventing heart failure.
• COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE
  申请人：Shy Therapeutics LLC

  公开号：US20200061037A1

  公开（公告）日：2020-02-27

  Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.